The study demonstrated cancer-type-specific inhibition of HSF1 by targeting an upstream oncogene activator, an approach that may apply to other tumor contexts where oncogenic drivers lead to HSF1-mediated increased chaperome expression [47]. Here, HSF1 is linked to cancer.